InvestorsHub Logo
Followers 5
Posts 593
Boards Moderated 0
Alias Born 06/11/2010

Re: Lunacy_John Galt post# 4884

Tuesday, 08/29/2017 4:53:19 AM

Tuesday, August 29, 2017 4:53:19 AM

Post# of 17447

Stellar management team, great science, Aspreva success, stellar VOC P2 results, expertise in trial design, FDA Fast Track status, etc. I simply believe that when you add it all up, it significantly boosts their odds of success in P3.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=133929331
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News